Using the ligand of FXR named obeticholic acid (OCA) has been proven to improve insulin sensitivity in phase II and III trials in patients with nonalcoholic steatohepatitis (NASH) [7]. This evidence concerns the gene INS and metabolic dysfunction-associated steatohepatitis.